[IPO Subscription] MSBio's First Day... Institutional Competition Rate 1,096.56 to 1, Offer Price at 7,800 Won
MSBio began its IPO subscription for general investors on the 12th. The medical device manufacturer will accept subscriptions for two days from the 12th to the 13th, with KB Securities serving as the underwriter. As of the morning of the 12th, the first day of subscription, the equal allocation of s
![[IPO Subscription] MSBio's First Day... Institutional Competition Rate 1,096.56 to 1, Offer Price at 7,800 Won](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F580134%2F631acbbd8afdeca6%2Foriginal.webp&w=1920&q=75)
MSBio began its IPO subscription for general investors on the 12th. The medical device manufacturer will accept subscriptions for two days from the 12th to the 13th, with KB Securities serving as the underwriter. As of the morning of the 12th, the first day of subscription, the equal allocation of shares stands at 37 shares per investor, with the confirmed offer price at 7,800 won.
Earlier, MSBio's institutional investor demand forecast competition rate was tallied at 1,096.56 to 1. The fact that it recorded a four-digit competition rate, surpassing three digits, indicates that institutional participation was relatively active. Whether this institutional interest will translate into general investor subscriptions is a key point of interest in this offering. However, a high institutional demand forecast competition rate does not guarantee a successful retail subscription or a post-listing stock price increase.
Future schedules have also been confirmed. After the subscription closes, allocation results will be announced on the 15th, with payment and refunds processed on the same day. The KOSDAQ listing date is set for October 22.
MSBio filed for a preliminary KOSDAQ listing review on April 16 and received approval on July 10. It then submitted its securities registration statement on September 7 and conducted the institutional investor demand forecast from September 28 to October 2.
The company's business area is medical devices utilizing human tissue and biomaterials. The company cites aging populations, the increase in chronic diseases, the expansion of the cosmetics and plastic surgery market, and advances in regenerative medicine technology as key drivers of industry growth. Notably, the company focuses on biomaterial medical devices aimed at tissue regeneration and the recovery of bodily functions, and it explained that such medical devices are gaining attention as a technological field that can complement the limitations of existing treatment methods. Biomaterial-based medical devices are a field where compatibility with the human body and safety are critical. Not only product performance but also raw material management, manufacturing processes, and quality maintenance capabilities can be factors in determining business competitiveness. MSBio stated that it operates the entire process—from raw material procurement to processing, manufacturing, quality control, and productization—based on its own technological capabilities. It also explained that it has established a production system that meets domestic and international medical device manufacturing and quality management standards (GMP) and related regulatory requirements. Through this, the company aims to secure product safety, efficacy, and quality reliability while strengthening its foundation for entering the global market. This KOSDAQ listing is significant as it marks MSBio's entry into the capital markets. Attention is focused on how its human tissue- and biomaterial-based medical device business will be evaluated by the market after listing. However, the industry's growth potential and individual companies' earnings growth need to be examined separately, as the expansion of the medical device market does not directly translate into revenue or profitability improvements for all companies. While the institutional demand forecast competition rate of 1,096.56 to 1 is a key indicator confirmed during this offering process, post-listing stock price movements may be influenced by various factors such as supply and demand and market conditions. MSBio's general subscription closes on the 13th. Following allocation and refund procedures on the 15th, the company is set to list on the KOSDAQ market on the 22nd. Following institutional investors' participation in the demand forecast, attention is now on what results the general subscription will yield. [This article was written based on the provided IPO schedule, institutional demand forecast competition rate, and the company's business description. Stock and IPO investments are high-risk investments that may result in principal loss, and the institutional demand forecast competition rate does not guarantee post-listing returns. This article is not intended to solicit investment, and investment decisions and responsibilities rest with the investor. The article was written with the assistance of AI.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.

![[Breaking] KOSPI Falls 1.97%, Slipping Below the 5,000 Mark for the First Time Since November 9](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581419%2F479dac739b049517%2Fvariants%2Fhero.webp&w=1920&q=75)

